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ORIGINAL BASIC SCIENCE STUDIES
The exact pathophysiologic mechanisms leading to
ulcer formation and impaired ulcer healing in patients
with chronic venous insufficiency has not been com-
pletely elucidated. Current theories relate the trapping,
migration, and activation of leukocytes—specifically,
macrophages, lymphocytes, and mast cells—with the
subsequent establishment of a chronic inflammatory
microenvironment.1-3 These theories have been con-
firmed by studies demonstrating the presence of pro-
inflammatory cytokines such as tumor necrosis factor-
α (TNF-α), interleukin-1β (IL-1β) and transforming
growth factor-β1 (TGF-β1) produced by these cell
types in venous ulcer wound fluid (VUWF)4,5 and in
the ulcer microenvironment.2,6,7
In previous experiments in our laboratory, we
demonstrated that a greater proportion of fibroblasts
cultured from venous ulcers were senescent when
compared with normal fibroblasts from the ipsilateral
limb of the same patient.8 Similar findings were made
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itive fibroblasts in vitro on culture day 12 (P = .02). TNF-α and TGF-β1 had similar
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for patients with venous reflux but no ulcers.9 Dermal
fibroblasts play a critical role during wound healing by
producing matrix proteins such as fibronectin, inte-
grins, collagen, and vitronectin to form a basal lamina
over which keratinocytes can migrate.
Cellular senescence has been implicated in
impaired healing through several potential mecha-
nisms, such as establishment of a proteolitic envi-
ronment and tissue immunoregulation.10-12 The
mechanism through which a great proportion of
dermal fibroblasts from venous ulcers become senes-
cent is not known. 
We hypothesized that exposure to the chronic
inflammatory microenvironment established by ve-
nous hypertension might be involved in the process
leading to fibroblast dysfunction and increased senes-
cence within the dermis of venous ulcers. VUWF is
considered a reflection of the microenvironment of
the venous ulcer, which may contain one or several
components with fibroblast-inhibitory activity and
from which these components are collected.
To test our hypothesis, we evaluated the in vitro
effect of VUWF on growth rates, cellular morpholo-
gy, and expression of senescence-associated β-galac-
tosidase activity (SA-β-Gal) on neonatal foreskin
fibroblasts (NFFs). We also tested the effect of pro-
inflammatory cytokines IL-1β, TNF-α, and TGF-β1,
known to be present in VUWF, in growth rate, in
morphology and in SA-β-Gal activity of NFFs.
METHODS
Patients
Patients, aged 35 to 75 years, with chronic venous
ulcer of greater than 2 months’ duration were inter-
viewed and examined. Evaluation of the severity of
venous disease in enrolled patients was determined by a
trained physician using the guidelines prepared by the
Executive Committee of the American Venous Forum
(“Clinical Classification and Grading of Chronic
Venous Disease”).13 Patients in whom concomitant
arterial disease was suspected, as evidenced by absent
pulses, patients whose ulcers were caused by malignan-
cy, and patients with infected ulcers were excluded from
the study. The Institutional Review Board at Boston
Medical Center approved this study, and informed con-
sent was obtained from all enrolled patients.
Collection of VUWF
Recruited patients were treated with foam wafer
occlusive dressing (Allevyn), which was placed over the
ulcer and covered by a paste bandage (Unna’s boot)
and a compression wrap. Dressings were changed
weekly, and VUWF was extracted from the foam wafer
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with a sterile syringe with a 20-gauge needle. The vol-
ume recovered from the dressings varied among
patients (0.3-3 mL). The collected VUWF was then
immediately diluted (1:10) with Dulbecco modified
Eagle medium (DMEM), which contained the pro-
tease inhibitor aprotinin (2 µg/mL) and phenyl-
methylsufonyl fluoride (10 µg/mL). The diluted
VUWF was filtered through a 0.2-µm tissue culture
filter unit to remove large debris, including bacteria.
Subsequently, the protein concentration (expressed as
µg/µL of VUWF) was determined and distributed
into 1-mL vials and kept frozen at –70˚C until further
testing. VUWF from four different donors was tested.
The average age of the patients was 50 years (range,
45-57 years); the only significant comorbidity report-
ed was coronary artery disease (one patient). All four
patients had a history of recurrent venous ulcers, and
the duration of the ulcer from which the VUWF was
collected was an average of 6 months.
Fibroblast isolation and culture
Cultured fibroblasts used in these experiments
were isolated from foreskins obtained from two
healthy neonates. NFFs have the highest growth
capacity among fibroblasts cultured from all age
groups.14,15 NFFs from the same donor were used in
each experiment to exclude the possibility of donor
variability. Neonatal foreskin was obtained within 2 to
6 hours of elective circumcision, and primary cultures
of dermal fibroblasts were prepared with techniques
described in detail by Stanley et al.16 In brief, biopsy
specimens were treated with a 5-minute povidone-
iodine bath followed by a 5-minute bath in 70%
ethanol. Overnight treatment with trypsin at 4˚C
(trypsin solution = 1 µg/mL) was performed, which
caused separation of the dermal tissue from the epi-
dermal and adipose tissue. The dermal tissue was iso-
lated under sterile conditions, cut sharply into 1- to 2-
mm fragments, and placed in etched plastic tissue
culture dishes. Complete medium (CM) that consist-
ed of DMEM with 10% calf serum and antibiotic solu-
tion (penicillin 100 U/mL, methicillin, fungizone
0.25 µg/mL, and streptomycin 100 µg/mL) was
added to support cell growth. Cells at the second pas-
sage were frozen (1 × 106 cells per vial) by using
dimethyl sulfoxide solution and were stored in liquid
nitrogen at –140˚C. A vial of frozen second-passage
cells was thawed and replated for each experiment. For
all growth-rate and morphology experiments, an equal
number of cells per plate (1500 cells/plate) were seed-
ed into 30-mm tissue culture dishes. For assessment of
SA-β-Gal activity, 1500 cells were seeded into 60-mm
tissue culture dishes.
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Growth curves
Growth curves were assessed by the plating of
fibroblasts at 1500 cells per plate and the determina-
tion of total cell number per plate with the use of a
Coulter counter, on days 7 and 11. A combination of
trypsin and ethylenediamine tetraacetic acid solution
was used to detach cells from tissue culture dishes,
and detachment was monitored by means of light
microscopy. Trypsin and ethylenediamine tetraacetic
acid action was neutralized with CM containing 10%
calf serum. Cells were then harvested and transferred
to plastic vials containing Isoton (Coulter Balanced
Electrolyte Solution, Coulter, Miami, Fla). Complete
harvesting of cells was reassessed by examining plates
under light microscopy. A Coulter counter was then
used for cell counting. Growth curves were generated
by the plotting of total cell number against harvesting
days. For each growth curve, the best-fit lines were
calculated using regression analysis, and the slopes of
those lines were used as estimates of the growth rates
of each cell population in cells per day (Fig 1).
VUWF. NFFs were cultured in the presence of
VUWF from four different donors, and growth
rates were obtained as explained above. The
amount of VUWF from each sample added to each
culture dish was standardized to a total protein con-
centration of 300 µg/mL, which meant the addi-
tion of 5 to 30 µL, depending on the sample, to the
total volume of CM (1.5 mL).
Pro-inflammatory cytokines. NFF growth rates
were also calculated in the presence of the following:
(1) TNF-α at three different final culture concentra-
tions (0.2, 2.0, 20 ng/mL), (2) IL-1β at three differ-
ent final culture concentrations (0.025, 0.25, and 2.5
ng/mL), (3) TGF-β1 at three different final culture
concentrations (0.1, 1.0, and 10 ng/mL), and (4)
combinations of the above cytokines with the highest
concentration of each one tested.
Cytokines were reconstituted as recommended
by the provider and added to CM to achieve the
highest concentration tested (5-10 µL). Further
dilutions were done by using CM. In addition, NFF
growth rates were calculated for TNF-α at a con-
centration of 20 ng/mL in four separate experi-
ments and for TGF-β1 at a concentration of 10
ng/mL in three separate experiments. Further test-
ing was not performed for IL-1β because no
inhibitory effect was observed in the preliminary
dose-response curves.
Assessment of senescence in vitro
For determination of SA-β-Gal activity, NFFs
were cultured in the presence of (1) complete media
alone, (2) VUWF from four different donors, (3)
Fig 1. Representative sample of growth curves of neonatal foreskin fibroblasts cultured in the
presence of complete media (squares) and in the presence of venous ulcer wound fluid (trian-
gles). The best-fit line for each curve was calculated by regression analysis and is shown for each
curve. The slope of this line (dotted line) was then calculated and used as an estimate of the
growth rate.
media. Anti-human TNF-α antibody–treated TNF
media was obtained by incubating TNF-α media
with 0.04 µg/mL of anti-human TNF-α antibody
for every 0.25 ng/mL of TNF-α (this is equivalent
to a neutralizing dose of 50%) for 60 minutes at
room temperature. Total cell count was then deter-
mined on day 11 of culture with a Coulter counter.
NFFs were then cultured in the presence of four
VUWF samples from four different ulcer patients
who were treated with and without anti-human
TNF-α antibody. The amount of anti-human TNF-
α antibody used was calculated by the amount of
TNF-α determined with ELISA for each VUWF
sample (0.04 µg/mL of anti-human TNF-α anti-
body for every 0.25 ng/mL of TNF-α). Bovine
serum albumin (250 µg) was added to CM for con-
trol purposes. A total of 250 g of VUWF protein was
used from each sample.
Materials
DMEM and trypsin were purchased from Gibco
BRL Life Technologies, Inc. (Gaithersburg, Md).
Bovine calf serum was obtained from Hyclone
Laboratories, Inc (Logan, Utah). X-Gal (5-bromo-
4-chloro-3-indolyl β-D-galactopyranoside) was pur-
chased from Sigma (St. Louis, Mo). Alevyn was
obtained from Smith & Nephew (Largo, Fla).
Cytokines (TNF-α, IL-1β, and TGF-β1) were pur-
chased from R&D Systems, Inc (Minneapolis,
Minn). Cytoscreen TNF-α US Ultrasensitive ELISA
kit was purchased from Biosource International, Inc
(Camarillo, Calif). Recombinant goat anti-human
TNF-α antibody was purchased from R & D
Systems, Inc (Minneapolis, Minn).
Statistical analyses
Linear regression analysis was used to estimate
the best-fit line for each growth rate obtained. The
slope of the best-fit line was used as an estimate of
the growth rate in cells per day ± SEM. Comparisons
of growth rates were done with two-tailed paired t-
test analysis, with significance represented by a P
value of less than .05. Paired t-test analysis was also
used to compare SA-β-Gal data.
RESULTS
Growth rates
VUWF. The average growth rate of NFFs in
CM was 42,727 ± 6301 cells/d with minimal vari-
ability between the two foreskin donors. The aver-
age NFF growth rate in the presence of VUWF was
3902 ± 2191 (P = .006). The average percent reduc-
tion of growth rates was 96% (86%-100%) (Fig 2).
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TNF-α at a final culture concentration of 20 ng/mL,
(4) TGF-β1 at a concentration of 10 ng/mL, and (5)
IL-1β at a concentration of 2.5 ng/mL. The effects
of CM alone, VUWF, and TNF-α were additionally
tested in three separate experiments to confirm the
preliminary findings.
SA-β-Gal activity determination with the use of X-
gal–based staining is a well-established method of
detecting senescent fibroblasts in vitro.17 SA-β-Gal
staining was performed according to a protocol
described by Dimri et al.17 Briefly, NFF cultures
exposed to the conditions described above were
allowed to achieve a 30% to 50% confluence at 37˚C
and 5% CO2. At this time, CM was removed, plates
were washed with sterile phosphate-buffered saline,
and fibroblasts were exposed to the staining solution
(20 mg/mL X-gal in dimethylformamide; 40
mmol/L citric acid/Na phosphate buffer, pH = 6.0; 
5 mmol/L potassium ferrocyanide; 5 mmol/L potasi-
um ferricyanide; 150 mmol/L sodium chloride; 2
mmol/L magnesium chloride; and H2O) after they
were fixed with 2% formaldehyde/0.2% glutaralde-
hyde in phosphate-buffered saline. Plates were incu-
bated for 12 to 16 hours (37˚C without CO2), and the
plates were then examined under light microscopy.
Positive cells characteristically display perinuclear pre-
cipitation of blue dye, which allows for clear identifica-
tion in standard light microscopy. The percentage of
positive SA-β-Gal cells was determined after a total of
300 to 400 cells per plate were counted.
Cell morphology
Morphologic light microscopic characteristics
were evaluated for NFFs in the presence of the above
culture conditions at ×10 and ×25 magnifications.
Determination of TNF-α concentration in
VUWF
Immunoreactive TNF-α was determined in five
different samples of VUWF, including those used in
NFF growth and senescence experiments. Enzyme-
linked immunosorbant assay (ELISA) (Cytoscreen
TNF-α US Ultrasensitive ELISA kit; Biosource
International, Inc, Camarillo, Calif) for human
TNF-α was used for this determination, with the
protocol provided by the manufacturer.
Effect of anti-human TNF-α antibody on the in
vitro inhibitory activity of VUWF
NFFs were plated in 35-mm tissue culture dish-
es and exposed to CM, CM containing TNF-α at a
final concentration of 20 ng/mL (TNF-α media),
and anti-human TNF-α antibody–treated TNF-α
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Cytokines. NFF growth rates were reduced in a
dose-dependent manner by TNF-α and by TGF-β1,
whereas IL-1β did not modify NFF growth rates at
the concentration tested (Fig 3).
Four separate experiments were performed with
the final TNF-α concentration of 20 ng/mL, with
an average NFF growth rate of 25,729 ± 5555
cells/d in the presence of TNF-α versus 46,099 ±
3453 cells/d in the presence of CM, a reduction of
56% (P = .01). NFF growth rates were inhibited by
TGF-β1 at a concentration of 10 ng/mL, but this
inhibitory effect did not reach statistical significance
(44,476 ± 4312 vs 24,500 ± 8422, P = .4).
No synergistic effects were noted when combi-
nations of the above cytokines were used, and the
inhibition observed was equivalent to that of the
TNF-α concentration used alone (data not shown). 
SA-β-Gal activity
The percentage of SA-β-Gal–positive NFFs after
12 days in culture was a mean of 2.56% ± 1.41% in the
presence of CM, versus 24.3% ± 6.2% in the presence
of VUWF (P = .009) and 34.8% ± 20.6% in the pres-
ence of TNF-α (P = .03) (Fig 4). In a single experi-
ment, TGF-β1 induced NFF SA-β-Gal activity to a
similar degree (23%), but no SA-β-Gal activity was
detected in NFFs cultured in the presence of IL-1β.
Cellular morphology
Morphologic changes were noted in an increased
proportion of fibroblasts cultured in the presence of
VUWF and TNF-α. These changes included
increase in size, polygonal and irregular shapes, and
presence of intracytoplasmatic stress fibers. These
changes are consistent with those previously report-
ed for senescent fibroblasts (Fig 5).
Fig 3. Neonatal foreskin fibroblast growth rates (± SEM)
when culture in the presence of tumor necrosis factor
(TNF)-α, transforming growth factor (TGF)-β, and inter-
leukin (IL)-1β. Dose-response curves were performed for
each cytokine. Each data point represents the growth rate
derived by calculating the slope of a 3-point growth curve.





Fig 2. Neonatal foreskin fibroblast growth rates in the
presence or absence of venous ulcer wound fluid (VUWF).
The VUWF bar represents the mean ± SEM of four dif-
ferent samples tested.
CM, Complete media; asterisk, P = .006
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Determination of TNF-α in VUWF
TNF-α was detected in all VUWF tested, with a
mean of 0.254 ± 19 ng/mL (range, 0.188-0.309
ng/mL).
Effect of anti-human TNF-α antibody on the in
vitro inhibitory activity of VUWF
Anti-human TNF-α antibody successfully
blocked the inhibitory effect of TNF-α in NFF cul-
tures exposed to a TNF-α concentration of 20
ng/mL (Table I). All VUWF samples tested in this
experiment inhibited NFF growth. Incubation of
VUWF samples in the presence of anti-human TNF-
α antibody did not significantly modify the in vitro
inhibitory effect of VUWF (Table II).
DISCUSSION
In this study, we have demonstrated that healthy
young fibroblasts are susceptible to VUWF. If we
accept that VUWF is a reflection of the venous ulcer
microenvironment, these findings demonstrate that
the dysfunction found on fibroblasts isolated from
patients with venous ulcers and venous reflux8,9 is a
direct consequence of the microenvironment estab-
lished by venous hypertension. In addition to the
reduction of NFF in vitro growth rates, VUWF also
increased the NFF expression of SA-β-Gal activity
and induced senescent-like morphologic characteris-
tics. This is consistent with the findings in our previ-
ous experiment, in which a greater proportion of
senescent fibroblasts were found on isolates from the
dermis of biopsy specimens taken from venous
ulcers.8 This suggests that the venous ulcer microen-
vironment affects fibroblast function, at least in part,
by inducing fibroblast senescence.
The inhibitory components of VUWF on fibro-
blast growth and function are not known. Potential
candidates include endogenously produced cytokines
involved in modulating chronic inflammation4; exten-
sively degraded vitronectin or fibronectin, which has
Table I. Average number of neonatal foreskin
fibroblasts (NFFs) ± SEM harvested from two sep-
arate tissue culture dishes counted after 11 days in
culture in the presence of complete media (CM),
CM + TNF-α (TNF-α), and CM + TNF-α + anti-
human TNF-α antibody (anti–TNF-α)
CM TNF-α Anti–TNF-α
NFFs 31,820 ± 1460 9805 ± 1965 21,760 ± 2860
The initial number of NFFs seeded was 500 cells. 
Fig 4. Neonatal foreskin fibroblast senescence associated β-galactosidase activity (SA-β-Gal)
activity after 12 days in culture in the presence of venous ulcer wound fluid (VUWF) and pro-
inflamatory cytokines. The VUWF bar represents the mean ± SEM of four different VUWF
samples tested. The tumor necrosis factor (TNF)-α bar represents the mean ± SEM of four
independent observations.
CM, Complete media; TGF-β, tranforming growth factor-β; IL-1β, interleukin-1β; asterisk, 
P < .03 when compared to control (CM).
JOURNAL OF VASCULAR SURGERY
740 Mendez et al October 1999
been shown to affect cellular adhesion18,19; or
increased levels of metalloproteases, which could lead
to an increased matrix breakdown.20 Bacterial toxins
or by-products have also been proposed.
Previous studies have demonstrated that
chronic wound fluid decreases the proliferation of
fibroblasts, keratinocytes, and endothelial cells in
vitro,21 in contrast to acute wound fluid, which
has been found to stimulate proliferation of
fibroblasts and endothelial cells.20,22 In previous
experiments in our laboratory, we have found that
chronic wound fluid is not cytotoxic to fibroblasts,
has a reversible inhibitory effect on NFF growth
rates, has inhibitory activity that is heat sensitive,
Table II. Average number of neonatal foreskin fibroblasts ± SEM harvested after 11 days in culture from
two separate dishes for each condition
CM-BSA VUWF 1 VUWF 2 VUWF 3 VUWF 4
CM-BSA 82,585 ± 5685 750 ± 20 56,550 ± 4515 205 ± 75 35,975 ± 905
Anti-TNF 91,190 ± 12,040 760 ± 140 22,470 ± 590 455 ± 135 32,440 ± 320
Venous ulcer wound fluid (VUWF; 250 µg of protein) from four different donors was tested after incubation with or without anti-human
TNF-α antibody (Anti-TNF). Bovine serum albumin (BSA, 250 µg) was added to complete media (CM) for control.
Fig 5. Representative photomicrographs of neonatal foreskin fibroblasts (NFFs) under light
microscopy at ×10 (1,2,3) and ×25 (4) magnification. All photomicrographs were obtained from
tissue culture plates subjected to the same culture conditions and on day 7 after initial seeding
(500 cells/plate). 1, NFFs cultured in the presence of complete media (CM) alone. 2, NFFs in
the presence of CM and venous ulcer wound fluid (VUWF). 3 and 4, NFFs in the presence of
TNF-α. The arrows mark fibroblasts with the typical morphologic features of senescence. 
and selectively inhibits other fast-growing cells
such as melanoma cell lines.29
Of the endogenously produced cytokines, pro-
inflammatory cytokines, such as IL-1β, TNF-α, and
TGF-β1, have previously been isolated from
VUWF.4 These pro-inflammatory cytokines play an
important beneficial role in the early stages of
wound healing and tissue repair, but their role in
chronic inflammatory processes like venous ulcers is
not known.
In our study, TNF-α and, in part, TGF-β1 had
an in vitro inhibitory effect on NFF growth rates.
The concentrations at which these inhibitory effects
were noted were significantly higher than those
expected physiologically within the venous ulcer
microenvironment but did reproduce, in part, the
effects of VUWF. Also, the inhibitory effects of
TNF-α and TGF-β1 may be dependent not only on
concentration but also on time of exposure. TNF-α,
a cytokine produced by macrophage upon activa-
tion, is a modulator of chronic inflammatory
responses, as well as TGF-β1, which is also largely
produced by activated macrophages and was detect-
ed in all VUWF tested in our experiments. IL-1β,
another pro-inflammatory cytokine, did not share
the same direct inhibitory activity on NFFs. In vivo
IL-1β could still play an indirect role in fibroblast
inhibition, modulating chronic inflammation. Other
pro-inflammatory cytokines not tested in our exper-
iments that could also be involved in this process are
interferon-γ and IL-12.23,24
The VUWF inhibitory effect on NFF was not
significantly modified by the blocking of VUWF
TNF-α activity, suggesting that, at least in vitro,
TNF-α plays a secondary role. This also suggests the
presence of unknown strong inhibitors of fibroblast
growth within VUWF.
Clinical improvement of venous ulcers has been
associated with decreased levels of VUWF TNF-α
concentration,5 and, in an experimental model, top-
ical application of TNF-α has been shown to be
detrimental to wound healing.27 Furthermore, a
prospective multicenter study of pentoxifylline (a
well-known down-regulator of TNF-α production)
in patients with venous ulcers demonstrated a signif-
icant reduction in ulcer size in treated patients com-
pared with untreated patients.28
VUWF, TNF-α, and TGF-β1, but not IL-1β,
induced NFF senescence in vitro. To our knowledge,
this effect has not yet been reported. Senescent fibro-
blasts are unable to replicate but remain metabolically
active with altered cell functions25; are less motile25;
can accumulate in tissue due to their resistance to
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apoptosis26; and produce a different array of proteins,
including elevated levels of matrix metalloproteases11
and pro-inflammatory cytokines10—all of which can
affect tissue integrity and normal healing.
CONCLUSIONS
We conclude that VUWF, through one or more of
its components, is able to inhibit NFF growth and
induce senescent characteristics. This suggests that the
venous hypertension microenvironment leads to sub-
sequent development of venous ulcers by inducing
severe fibroblast dysfunction. Accumulation of TNF-α
and TGF-β1 in this microenvironment may contribute
significantly to this process. Further studies are needed
to isolate other fibroblast inhibitory components of
VUWF and to elucidate the role of pro-inflammatory
cytokines in chronic venous insufficiency.
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Dr John Mannick (Boston, Mass). Manuel, I’d like to
congratulate you and Dr. Menzoian and your associates
for pursuing this very important clinical problem at the
molecular and the cellular levels.
I have a couple of problems with the data, which per-
haps you can straighten me out on.
The first has to do with your control cultures, which
contain 10% fetal calf serum. Now, what did you actually
do with the wound fluid? Did you just filter the wound
fluid, determine what its protein concentration was, and
then put the cultures in that fluid, at a protein concentra-
tion of 300 µg/mL? Is that what you did?
Dr Manuel V. Mendez. Once the wound fluid was
obtained, we filtered and diluted it in culture media with-
out calf serum.
Dr Mannick. Is it not possible that the entire differ-
ence we’re looking at here is just the absence of fetal calf
serum in the culture?
Dr Mendez. We cultured the cells in 1.5 mL of CM
including 10% calf serum. When we measured our concen-
tration of protein in the wound fluid, it was an average of 6
µg/µL. This meant that we usually added anywhere between
25 and 50 µL per plate, so we think that even though this
wound fluid does not have the protein concentration of calf
serum, there was enough calf serum to support growth.
Dr Mannick. So, if I understand you correctly, then
you have these cells still in medium with 10% calf serum,
but you’ve added some of the wound fluid in there, in
addition to the regular medium containing the calf serum.
Dr Mendez. Exactly. That’s the way we did it.
Dr Mannick. Do you think that it might be a good
idea to do a control that had some human serum, from the
same patient or a different patient, that was treated the
same way as your wound fluid? And then add it just to
make sure that diluting out the fetal calf serum doesn’t
explain the results?
Dr Mendez. Yes, I think that’s a good point. We
should probably, to get the ideal control, use the same
amount of volume used for the VUWF media.
Dr Mannick. Yes, I would think so.
The second problem I have is with the TNF experi-
ments. The TNF concentration in your wound fluid is
about 200 pg/mL, which is very believable in an area of
inflammation. But, the only concentration of TNF that
really did any statistically significant damage to your cul-
tures was, if I recall your data correctly, 20 ng.
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That’s 200 times the physiologic concentration of TNF.
So I can’t believe that the TNF concentration in that wound
fluid and the concentration that caused the damage could
really be said to be similar and that TNF is the explanation.
I think you’re going to have to look elsewhere, besides
TNF, to explain your findings.
Dr Mendez. Yes.
I think that there are definitely other inhibitors, com-
ponents of VUWF, which we have not identified.
I didn’t mean to make a connection between the level
of TNF and VUWF as a direct cause of the inhibitor activ-
ity in vitro. The issue that we find inhibitor activity of TNF
in vitro just points out the possibility that TNF in vivo may
have an effect in terms of fibroblast function and in terms
of fibroblast senescence.
Dr Mannick. Well, I guess, just in defense of what I said,
20,000 pg/mL of TNF should be pretty toxic to any cell I
can think of. So I think probably the 200 pg dose, which
didn’t do much to your cultures, cannot really explain the
findings. I certainly would agree with you there.
Dr B. Sumpio (New Haven, Conn). I’d like to follow
up with three questions.
One is a follow up on Dr. Mannick’s point, regarding
the causality issue of TNF, as you stated in your abstract—
venous fluid. And he’s made a point already, concerning
the doses.
I guess the killer experiment, if you will, is to really
add some kind of neutralizing antibody. If you were, per-
haps, to add a neutralizing antibody to TNF, or to IL-1,
or whatever you’d like to pick, and you found that you
could attenuate that response, then that might give more
evidence that TNF is involved.
So, the first question is, have you done any neutraliz-
ing antibody studies to support the contention of TNF-α
or other cytokines in this role?
Dr Mendez. No. We are in the process of planning out
those experiments, but we have not done those studies yet.
I want to mention one thing, that there are clinical
data in the literature to support that anti-TNF therapy
may have an effect in venous ulcer healing. We know
about the beneficial effects of using pentoxifylline in a ran-
domized trial for venous ulcer healing. And we know that
pentoxifylline has regulating activity of TNF, among other
effects. This is indirect evidence that maybe by blocking
TNF we can induce healing on venous ulcers.
Also Salomon et al showed that topical application of
TNF decreases wound healing strength and increases the
level of collagenoses and diminishes RNA for procologen
type one and two. Again, we have not done the studies neu-
tralizing TNF within the wound fluid, and we show that
actually blunts the inhibitory effect on neonatal fibroblasts.
Dr Sumpio. And just to be quick, the next question real-
ly is, have you looked at the effects of this fluid in other cell
types, besides fibroblasts? For instance, on the endothelium
cell, or to see if this has an effect, and would you tell us more
about the senescence effect? Is it truly senescence? Are you
killing cells? Is it lytic to the cells, or is it causing apoptosis?
Dr Mendez. In our lab, we’ve done studies with
VUWF showing, first of all, that it’s not cytotoxic. We’ve
also tried VUWF in other cell types, and it appears to be
inhibitory for fast growing cells, such as melanoma cell
lines, but not for slow growing cells, like melanocytes.
We think that this inhibitory effect has to do with the
growth rate. And we see here, that there is significant
inhibitory activity on NFFs. It’s probably related to the
growth rate of the cells.
Dr Allan Callow (Boston, Mass). Manuel, I think it’s
time to rally around the flag. And therefore I’m getting up
to say what a splendid study I think this is.
It’s not a Nobel Prize winner, but I think it’s a very
good piece of work.
I, too, have some questions. I wonder if you would see
the same effect with endothelial cells or muscle cells.
I also wonder if, because β-galactosidase is such a
ubiquitous substance and associated with trauma, whether
or not you might demonstrate some of this effect if you
had just a simple acute wound, a dermabrasion, or an open
wound and took the serum.
But overall, I want to say that I think it’s a step for-
ward. And of course it’s one small step but, nevertheless,
a very important one.
Dr Mendez. Thank you, Dr. Callow.
We have not tested VUWF, nor have we looked at
senescence in other cell types, yet.
There is one comment I want to make about acute
wounds and chronic wounds. There are studies out in the
literature showing that fluid that came from acute wounds
has the opposite effect. It stimulates fibroblast prolifera-
tion as well as collagen activity. So, I think there is a dis-
tinction to make between chronic wounds, like venous
ulcers, and acute wounds.
I think it would be interesting to look at the acute set-
ting, whether fibroblasts obtained from those wounds do
actually behave like senescent cells. But we have not done
that type of study yet.
Dr Robert Hopkins (Providence, RI). Perhaps I
missed it, but I didn’t hear you mention the possible
microbiology of the ulcer fluid. The wound is open and,
to some extent, subject to contamination for a long time.
I assume you cultured it and that it was negative. On the
other hand, there could be other microorganisms there
that did not grow out. Could they have contributed to
your findings?
Dr Mendez. The inhibitory effect of VUWF could be
caused by components of exogenous nature such as bacte-
rial toxins or could be of endogenous origin.
We filtered this fluid through filters that remove all
bacteria, but some toxins produced by bacteria may actu-
ally go through.
The issue that we don’t see bacteria overgrowth in our
cultures makes us very confident that there’s no contamina-
tion of bacteria, but we cannot rule out the possibility of bac-
terial toxins within the VUWF as potential inhibitors for
fibroblast function, as well as inducers of senescence.
